Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Zai Lab announcesChina NMPA priority review for ripretinib NDA » 07:44
08/04/20
08/04
07:44
08/04/20
07:44
ZLAB

Zai Lab

$79.71 /

+3.53 (+4.63%)

Zai Lab announced that…

Zai Lab announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted priority review status to the New Drug Application for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib targets the broad spectrum of KIT and PDGFRalpha mutations known to drive GIST.

ShowHide Related Items >><<
ZLAB Zai Lab
$79.71 /

+3.53 (+4.63%)

ZLAB Zai Lab
$79.71 /

+3.53 (+4.63%)

07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/08/20 Guggenheim
Zai Lab price target raised to $105 from $75 at Guggenheim
07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
ZLAB Zai Lab
$79.71 /

+3.53 (+4.63%)

  • 23
    Jan
Over a week ago
Hot Stocks
Zai Lab receives China NMPA acceptance of NDA submission of ripretinib » 07:34
07/20/20
07/20
07:34
07/20/20
07:34
ZLAB

Zai Lab

$83.70 /

+0.205 (+0.25%)

, DCPH

Deciphera

$51.89 /

-1.56 (-2.92%)

Zai Lab (ZLAB) and…

Zai Lab (ZLAB) and Deciphera Pharmaceuticals (DCPH) announced that the China National Medical Products Administration has accepted its New Drug Application for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib was recently granted full approval by the U.S. Food and Drug Administration for the treatment of fourth-line GIST. Ripretinib is also approved by Health Canada for the treatment of adult patients with advanced GIST who have received prior treatment with imatinib, sunitinib, and regorafenib and by the Australian Therapeutic Goods Administration for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib. INVICTUS is a Phase 3 randomized, double-blind, placebo-controlled, international, multicenter clinical study designed to evaluate the safety, tolerability, and efficacy of ripretinib compared to placebo in 129 patients with advanced GIST whose previous therapies have included imatinib, sunitinib, and regorafenib. Patients were randomized 2:1 to either 150 mg of ripretinib or placebo once daily. The primary efficacy endpoint was progression-free survival as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors. As previously reported, the median PFS in the study was 6.3 months compared to 1.0 month in the placebo arm, with significantly reduced the risk of disease progression or death of 85%. Secondary endpoints as determined by independent radiologic review using modified RECIST included Objective Response Rate and Overall Survival. Ripretinib demonstrated an ORR of 9.4% compared with 0% for placebo. Ripretinib also demonstrated a median OS of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64%. The most common adverse reactions were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, and vomiting. Adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received ripretinib.

ShowHide Related Items >><<
ZLAB Zai Lab
$83.70 /

+0.205 (+0.25%)

DCPH Deciphera
$51.89 /

-1.56 (-2.92%)

ZLAB Zai Lab
$83.70 /

+0.205 (+0.25%)

07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/08/20 Guggenheim
Zai Lab price target raised to $105 from $75 at Guggenheim
07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
DCPH Deciphera
$51.89 /

-1.56 (-2.92%)

07/07/20 Piper Sandler
Deciphera estimates raised on 'exceedingly bullish' survey at Piper Sandler
05/18/20 Truist
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
ZLAB Zai Lab
$83.70 /

+0.205 (+0.25%)

DCPH Deciphera
$51.89 /

-1.56 (-2.92%)

  • 14
    Feb
  • 23
    Jan
  • 15
    Aug
  • 01
    Aug
DCPH Deciphera
$51.89 /

-1.56 (-2.92%)

Recommendations
Turning Point agreement with Zai Lab favorable, says Roth Capital » 16:13
07/09/20
07/09
16:13
07/09/20
16:13
TPTX

Turning Point Therapeutics

$60.78 /

-1.955 (-3.12%)

, ZLAB

Zai Lab

$89.19 /

+2.32 (+2.67%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah views Turning Point Therapeutics' (TPTX) agreement with Zai Lab (ZLAB) for the development and commercialization of repotrectinib in Greater China as favorable. The agreement monetizes repotrectinib in a territory that is difficult to monetize, builds an incentive for Zai to support the drug's current development, and establishes a relationship to support Turning Point's commercialization of other pipeline drugs in China, Jallah tells investors in a research note. The analyst keeps a Buy rating on Turning Point with a $75 price target.

ShowHide Related Items >><<
ZLAB Zai Lab
$89.19 /

+2.32 (+2.67%)

TPTX Turning Point Therapeutics
$60.78 /

-1.955 (-3.12%)

TPTX Turning Point Therapeutics
$60.78 /

-1.955 (-3.12%)

07/09/20 Oppenheimer
Turning Point Therapeutics initiated with an Outperform at Oppenheimer
07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
05/26/20 H.C. Wainwright
Turning Point price target raised to $88 from $72 at H.C. Wainwright
05/14/20 Roth Capital
Turning Point Therapeutics price target raised to $75 from $65 at Roth Capital
ZLAB Zai Lab
$89.19 /

+2.32 (+2.67%)

07/08/20 Guggenheim
Zai Lab price target raised to $105 from $75 at Guggenheim
07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
ZLAB Zai Lab
$89.19 /

+2.32 (+2.67%)

TPTX Turning Point Therapeutics
$60.78 /

-1.955 (-3.12%)

  • 19
    May
  • 23
    Jan
  • 06
    Sep
  • 01
    Aug
Recommendations
Zai Lab price target raised to $105 from $75 at Guggenheim » 07:17
07/08/20
07/08
07:17
07/08/20
07:17
ZLAB

Zai Lab

$82.86 /

+0.75 (+0.91%)

Guggenheim analyst Seamus…

Guggenheim analyst Seamus Fernandez raised the firm's price target on Zai Lab (ZLAB) to $105 from $75 and keeps a Buy rating on the shares following the agreement with Turning Point (TPTX) wherein Zai Lab obtains exclusive development and commercialization rights for repotrectinib in Greater China. The analyst believes this deal is another example of Zai Lab's continued best-in-class licensing strategy in oncology.

ShowHide Related Items >><<
ZLAB Zai Lab
$82.86 /

+0.75 (+0.91%)

ZLAB Zai Lab
$82.86 /

+0.75 (+0.91%)

07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
ZLAB Zai Lab
$82.86 /

+0.75 (+0.91%)

  • 23
    Jan
  • 01
    Aug
Over a month ago
Recommendations
Zai Lab price target raised to $93 from $79 at SVB Leerink » 13:11
07/07/20
07/07
13:11
07/07/20
13:11
ZLAB

Zai Lab

$84.82 /

+2.71 (+3.30%)

, TPTX

Turning Point Therapeutics

$62.95 /

+0.2 (+0.32%)

SVB Leerink analyst…

SVB Leerink analyst Jonathan Chang raised the firm's price target on Zai Lab (ZLAB) to $93 from $79 and keeps an Outperform rating on the shares after the company announced an exclusive license agreement for the development and commercialization of Turning Point Therapeutics' (TPTX) lead drug candidate, repotrectinib, in Greater China. He views the deal as a strategic addition to the pipeline as Zai Lab continues to broaden its core oncology indications, the analyst tells investors.

ShowHide Related Items >><<
ZLAB Zai Lab
$84.82 /

+2.71 (+3.30%)

TPTX Turning Point Therapeutics
$62.95 /

+0.2 (+0.32%)

ZLAB Zai Lab
$84.82 /

+2.71 (+3.30%)

07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
TPTX Turning Point Therapeutics
$62.95 /

+0.2 (+0.32%)

05/26/20 H.C. Wainwright
Turning Point price target raised to $88 from $72 at H.C. Wainwright
05/14/20 Roth Capital
Turning Point Therapeutics price target raised to $75 from $65 at Roth Capital
05/14/20 Roth Capital
Turning Point Therapeutics price target raised to $75 from $65 at Roth Capital
05/13/20 SVB Leerink
Turning Point Therapeutics price target raised to $67 from $60 at SVB Leerink
ZLAB Zai Lab
$84.82 /

+2.71 (+3.30%)

TPTX Turning Point Therapeutics
$62.95 /

+0.2 (+0.32%)

  • 19
    May
  • 23
    Jan
  • 06
    Sep
  • 01
    Aug
Hot Stocks
Turning Point Therapeutics, Zai Lab announce license agreement for repotrectinib » 07:36
07/07/20
07/07
07:36
07/07/20
07:36
TPTX

Turning Point Therapeutics

$62.75 /

-1.71 (-2.65%)

, ZLAB

Zai Lab

$82.11 /

+0.95 (+1.17%)

Turning Point…

Turning Point Therapeutics (TPTX) and Zai Lab (ZLAB) announced an exclusive license agreement for the development and commercialization of Turning Point's lead drug candidate, repotrectinib, in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25M upfront payment, with potential to receive up to an additional $151M in development, regulatory and sales-based milestone payments. Turning Point will also be eligible to receive mid-to-high teen royalties based on annual net sales of repotrectinib in Greater China. Zai Lab anticipates opening additional sites for the TRIDENT-1 Phase 2 registrational clinical study of repotrectinib. The ongoing study is currently active in 11 countries globally and enrolling patients with ROS1-positive advanced non-small cell lung cancer, or NSCLC, and NTRK-positive solid tumors.

ShowHide Related Items >><<
ZLAB Zai Lab
$82.11 /

+0.95 (+1.17%)

TPTX Turning Point Therapeutics
$62.75 /

-1.71 (-2.65%)

TPTX Turning Point Therapeutics
$62.75 /

-1.71 (-2.65%)

05/26/20 H.C. Wainwright
Turning Point price target raised to $88 from $72 at H.C. Wainwright
05/14/20 Roth Capital
Turning Point Therapeutics price target raised to $75 from $65 at Roth Capital
05/14/20 Roth Capital
Turning Point Therapeutics price target raised to $75 from $65 at Roth Capital
05/13/20 SVB Leerink
Turning Point Therapeutics price target raised to $67 from $60 at SVB Leerink
ZLAB Zai Lab
$82.11 /

+0.95 (+1.17%)

07/06/20 Mizuho
Novocure has large growth opportunity in China, says Mizuho
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
ZLAB Zai Lab
$82.11 /

+0.95 (+1.17%)

TPTX Turning Point Therapeutics
$62.75 /

-1.71 (-2.65%)

  • 19
    May
  • 23
    Jan
  • 06
    Sep
  • 01
    Aug
Recommendations
Novocure has large growth opportunity in China, says Mizuho » 07:18
07/06/20
07/06
07:18
07/06/20
07:18
NVCR

Novocure

$60.64 /

+0.995 (+1.67%)

, ZLAB

Zai Lab

$81.16 /

+1.43 (+1.79%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang reiterates a Buy rating on Novocure (NVCR) with an $82 price target following the launch of Optune for glioblastoma multiforme in China. Optune is a "significant improvement" over the current standard of care in China, and patient demand should be robust, Yang tells investors in a research note. Further, Chinese patients have shown a willingness to pay for premium cancer treatments out of pocket, adds the analyst. Yang believes the glioblastoma multiforme market in China offers Novocure a "substantial" growth opportunity via its partnership with Zai Lab (ZLAB).

ShowHide Related Items >><<
ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

NVCR Novocure
$60.64 /

+0.995 (+1.67%)

NVCR Novocure
$60.64 /

+0.995 (+1.67%)

05/20/20 Piper Sandler
Novocure remains top idea in oncology equipment at Piper Sandler
05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/01/20 Truist
Novocure price target lowered to $90 from $105 at SunTrust
05/01/20 Oppenheimer
Novocure downgraded to Perform on pipeline delays at Oppenheimer
ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
ZLAB Zai Lab
$81.16 /

+1.43 (+1.79%)

NVCR Novocure
$60.64 /

+0.995 (+1.67%)

  • 23
    Jan
  • 01
    Aug
NVCR Novocure
$60.64 /

+0.995 (+1.67%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
LFC

China Life Insurance

$10.27 /

+0.03 (+0.29%)

, ZLAB

Zai Lab

$78.20 /

-0.42 (-0.53%)

, EH

Ehang

$11.40 /

+0.1 (+0.88%)

, DL

China Distance Education

$8.67 /

+0.2 (+2.36%)

China Investor Virtual…

China Investor Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
ZLAB Zai Lab
$78.20 /

-0.42 (-0.53%)

EH Ehang
$11.40 /

+0.1 (+0.88%)

DL China Distance Education
$8.67 /

+0.2 (+2.36%)

LFC China Life Insurance
$10.27 /

+0.03 (+0.29%)

03/16/20 CLSA
China Life Insurance upgraded to Buy at CLSA with sector at 'life low'
03/16/20 CLSA
China Life Insurance upgraded to Buy from Outperform at CLSA
01/06/20 CLSA
China Life Insurance upgraded to Outperform from Underperform at CLSA
10/30/19 CIMB
China Life Insurance upgraded to Hold from Reduce at CIMB
ZLAB Zai Lab
$78.20 /

-0.42 (-0.53%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
EH Ehang
$11.40 /

+0.1 (+0.88%)

02/07/20 Needham
Ehang initiated with a Buy at Needham
DL China Distance Education
$8.67 /

+0.2 (+2.36%)

ZLAB Zai Lab
$78.20 /

-0.42 (-0.53%)

EH Ehang
$11.40 /

+0.1 (+0.88%)

DL China Distance Education
$8.67 /

+0.2 (+2.36%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
LFC

China Life Insurance

$10.24 /

+ (+0.00%)

, ZLAB

Zai Lab

$78.62 /

-2.45 (-3.02%)

, EH

Ehang

$11.30 /

-0.6 (-5.04%)

, DL

China Distance Education

$8.47 /

-0.155 (-1.80%)

China Investor Virtual…

China Investor Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
ZLAB Zai Lab
$78.62 /

-2.45 (-3.02%)

EH Ehang
$11.30 /

-0.6 (-5.04%)

DL China Distance Education
$8.47 /

-0.155 (-1.80%)

LFC China Life Insurance
$10.24 /

+ (+0.00%)

03/16/20 CLSA
China Life Insurance upgraded to Buy at CLSA with sector at 'life low'
03/16/20 CLSA
China Life Insurance upgraded to Buy from Outperform at CLSA
01/06/20 CLSA
China Life Insurance upgraded to Outperform from Underperform at CLSA
10/30/19 CIMB
China Life Insurance upgraded to Hold from Reduce at CIMB
ZLAB Zai Lab
$78.62 /

-2.45 (-3.02%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
EH Ehang
$11.30 /

-0.6 (-5.04%)

02/07/20 Needham
Ehang initiated with a Buy at Needham
DL China Distance Education
$8.47 /

-0.155 (-1.80%)

ZLAB Zai Lab
$78.62 /

-2.45 (-3.02%)

EH Ehang
$11.30 /

-0.6 (-5.04%)

DL China Distance Education
$8.47 /

-0.155 (-1.80%)

Conference/Events
JPMorgan to hold a virtual conference » 08:55
06/22/20
06/22
08:55
06/22/20
08:55
LFC

China Life Insurance

$10.24 /

-0.06 (-0.58%)

, ZLAB

Zai Lab

$81.07 /

+5.29 (+6.98%)

, EH

Ehang

$11.90 /

+0.05 (+0.42%)

, DL

China Distance Education

$8.63 /

+0.145 (+1.71%)

China Investor Virtual…

China Investor Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
ZLAB Zai Lab
$81.07 /

+5.29 (+6.98%)

EH Ehang
$11.90 /

+0.05 (+0.42%)

DL China Distance Education
$8.63 /

+0.145 (+1.71%)

LFC China Life Insurance
$10.24 /

-0.06 (-0.58%)

03/16/20 CLSA
China Life Insurance upgraded to Buy at CLSA with sector at 'life low'
03/16/20 CLSA
China Life Insurance upgraded to Buy from Outperform at CLSA
01/06/20 CLSA
China Life Insurance upgraded to Outperform from Underperform at CLSA
10/30/19 CIMB
China Life Insurance upgraded to Hold from Reduce at CIMB
ZLAB Zai Lab
$81.07 /

+5.29 (+6.98%)

05/13/20 Piper Sandler
Piper says Novocure opens up largest GBM market with China approval
05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
EH Ehang
$11.90 /

+0.05 (+0.42%)

02/07/20 Needham
Ehang initiated with a Buy at Needham
DL China Distance Education
$8.63 /

+0.145 (+1.71%)

ZLAB Zai Lab
$81.07 /

+5.29 (+6.98%)

EH Ehang
$11.90 /

+0.05 (+0.42%)

DL China Distance Education
$8.63 /

+0.145 (+1.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.